Zacks Investment Research lowered shares of Edap Tms (NASDAQ:EDAP) from a hold rating to a sell rating in a research note issued to investors on Monday, Zacks.com reports.
According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “
A number of other research analysts have also recently issued reports on the company. TheStreet cut Timkensteel from a c- rating to a d+ rating in a research note on Monday, June 17th. ValuEngine upgraded YY from a sell rating to a hold rating in a research note on Friday, June 7th. Finally, HC Wainwright set a $4.00 price objective on Uranium Energy and gave the company a buy rating in a research note on Tuesday, June 11th.
Shares of EDAP traded up $0.03 on Monday, reaching $2.71. The stock had a trading volume of 19,400 shares, compared to its average volume of 173,521. The firm has a market capitalization of $81.19 million, a price-to-earnings ratio of 135.00 and a beta of 1.94. The company has a quick ratio of 1.97, a current ratio of 2.40 and a debt-to-equity ratio of 0.09. The company’s 50-day moving average price is $2.83. Edap Tms has a 12-month low of $1.35 and a 12-month high of $5.42.
Edap Tms (NASDAQ:EDAP) last announced its quarterly earnings data on Wednesday, May 15th. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.01. The business had revenue of $11.50 million during the quarter, compared to analysts’ expectations of $13.25 million. Edap Tms had a negative return on equity of 1.13% and a negative net margin of 0.36%. As a group, sell-side analysts predict that Edap Tms will post 0.08 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Edap Tms stock. Fosun International Ltd increased its holdings in shares of Edap Tms SA (NASDAQ:EDAP) by 45.9% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 363,485 shares of the medical equipment provider’s stock after purchasing an additional 114,342 shares during the quarter. Fosun International Ltd owned 1.25% of Edap Tms worth $1,072,000 as of its most recent filing with the SEC. 10.31% of the stock is currently owned by institutional investors and hedge funds.
Edap Tms Company Profile
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
Read More: Asset Allocation
Get a free copy of the Zacks research report on Edap Tms (EDAP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.